137 results on '"Paris Kosmidis"'
Search Results
102. Combination docetaxel (Taxotere), fluorouracil, and leucovorin (TFL), as first-line chemotherapy in advanced gastric cancer: a Hellenic Cooperative Oncology Group phase II study
- Author
-
Athanassios Sakantamis, George Fountzilas, Dimitrios Bafaloukos, D. Tsavdaridis, Dimosthenis Skarlos, N. Xiros, Aristotelis Bamias, Pavlos Papakostas, Dimitrios Janinis, Paris Kosmidis, and Haralabos P. Kalofonos
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Maximum Tolerated Dose ,medicine.medical_treatment ,Leucovorin ,Phases of clinical research ,Docetaxel ,Surgical oncology ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,neoplasms ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Gastroenterology ,General Medicine ,Advanced gastric cancer ,Middle Aged ,digestive system diseases ,Survival Rate ,Fluorouracil ,Female ,Taxoids ,First line chemotherapy ,business ,therapeutics ,medicine.drug - Abstract
We assessed the efficacy and safety profile of a docetaxel (Taxotere; Sanofi-Aventis, France), fluorouracil (FU), and leucovorin (LV) combination (TFL), as first-line chemotherapy in patients with advanced gastric cancer.Fifty-eight patients with advanced gastric cancer were entered in this phase II study. The chemotherapy regimen (TFL) was administered in an outpatient setting as follows: docetaxel 7 mg/m2 on day 1 and FU 50 mg/m2 and LV 30 mg/m2 on days 1 to 3, every 3 weeks for six cycles.On an intent-to-treat basis, 4 complete (7%) and 11 partial responses (19%) were observed, with an objective overall response rate of 26%; in addition, 22 patients (38%) had stable and 15 (26%) had progressive disease. For 6 (10%) patients, response could not be evaluated. Responses were noted at all metastatic sites. With a median follow-up of 55 months, median survival was 9 months; median time to progression, 5.9 months; and median duration of response, 10 months. Toxicity was manageable and no toxic death was reported. Neutropenia was the most frequent severe toxicity and occurred in 30% of the patients. The main non-hematologic toxicities were alopecia (76%), diarrhea (30%), and stomatitis (30%).The results of this phase II study seem to indicate that the TFL regimen has moderate activity in patients with advanced gastric cancer, with acceptable toxicity.
- Published
- 2005
103. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study
- Author
-
Dimosthenis V, Skarlos, Haralabos P, Kalofonos, George, Fountzilas, Meletios A, Dimopoulos, Nicholas, Pavlidis, Evangelia, Razis, Theofanis, Economopoulos, Dimitrios, Pectasides, Helen, Gogas, Paris, Kosmidis, Dimitrios, Bafaloukos, George, Klouvas, George, Kyratzis, and Gerasimos, Aravantinos
- Subjects
Adult ,Aged, 80 and over ,Ovarian Neoplasms ,Organoplatinum Compounds ,Middle Aged ,Deoxycytidine ,Gemcitabine ,Drug Administration Schedule ,Drug Resistance, Multiple ,Doxorubicin ,Drug Resistance, Neoplasm ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Female ,Taxoids ,Aged - Abstract
A phase II study was conducted to evaluate the efficacy and toxicity of the combination of gemcitabine (GEM) and pegylated liposomal doxorubicin (PLD) in patients with platinum- and/or taxane-resistant/refractory advanced epithelial ovarian cancer (AEOC).Patients (pts), who had been treated with platinum or paclitaxel and met the criteria of resistant/refractory AEOC, received GEM 650 mg/m2 days 1 and 8 and PLD 25 mg/m2 day 1 every 4 weeks up to a total of 6 cycles, unless disease progression or adverse effects prohibited further therapy.Thirty-seven patients entered the study. There was 1 complete (3%) and 7 partial responses (19%) for an overall response rate of 22%. Two patients had stable disease (5.5%). After a median follow-up of 16.2 months, the median survival was 8.4 months and time to treatment failure 2.7 months. The most frequent severe toxicity was myelosuppression recorded in 13 (35%) patients. Severe stomatitis was recorded in only 2 (5%) cases and severe palmar-plantar erythrodysesthesia in 1 patient. One severe allergic reaction (grade 4) to PLD was recorded following the third cycle of treatment.The combination of GEM and PLD in patients with AEOC, who are resistant/ refractory to platinum and/or Taxanes, did not show any superiority over monotherapy. However, in view of the acceptable toxicity profile, the above combination may deserve further investigation in a randomised setting.
- Published
- 2005
104. ESMO Handbook of Oncological Emergencies
- Author
-
Dirk Schrijvers, Sylvie Rottey, Paris Kosmidis, and Fabrice Andre
- Subjects
business.industry ,Medicine ,business - Published
- 2005
105. Characterization of a novel large deletion and single point mutations in the BRCA1 gene in a Greek cohort of families with suspected hereditary breast cancer
- Author
-
Nikos Pandis, Georgios Nasioulas, Vasiliki Gaki, Paris Kosmidis, Ioulia Belogianni, E. Razi, Andreas Hadjisavvas, Stefanos Labropoulos, Kyriacos Kyriacou, M Mihalatos, Angela Apessos, Andreas Petounis, Drakoulis Yannoukakos, and Antonios Keramopoulos
- Subjects
Cancer Research ,endocrine system diseases ,Genes, BRCA2 ,Genes, BRCA1 ,Mutation, Missense ,Breast Neoplasms ,Biology ,lcsh:RC254-282 ,Germline mutation ,Breast cancer ,Surgical oncology ,medicine ,Genetics ,Humans ,Point Mutation ,Age of Onset ,skin and connective tissue diseases ,Gene ,Germ-Line Mutation ,Polymorphism, Genetic ,Greece ,Point mutation ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,humanities ,Pedigree ,Oncology ,Cohort ,Female ,Chromosome Deletion ,Age of onset ,Ovarian cancer ,Research Article - Abstract
Background Germline mutations in BRCA1 and BRCA2 predispose to breast and ovarian cancer. A multitude of mutations have been described and are found to be scattered throughout these two large genes. We describe analysis of BRCA1 in 25 individuals from 18 families from a Greek cohort. Methods The approach used is based on dHPLC mutation screening of the BRCA1 gene, followed by sequencing of fragments suspected to carry a mutation including intron – exon boundaries. In patients with a strong family history but for whom no mutations were detected, analysis was extended to exons 10 and 11 of the BRCA2 gene, followed by MLPA analysis for screening for large genomic rearrangements. Results A pathogenic mutation in BRCA1 was identified in 5/18 (27.7 %) families, where four distinct mutations have been observed. Single base putative pathogenic mutations were identified by dHPLC and confirmed by sequence analysis in 4 families: 5382insC (in two families), G1738R, and 5586G > A (in one family each). In addition, 18 unclassified variants and silent polymorphisms were detected including a novel silent polymorphism in exon 11 of the BRCA1 gene. Finally, MLPA revealed deletion of exon 20 of the BRCA1 gene in one family, a deletion that encompasses 3.2 kb of the gene starting 21 bases into exon 20 and extending 3.2 kb into intron 20 and leads to skipping of the entire exon 20. The 3' breakpoint lies within an AluSp repeat but there are no recognizable repeat motifs at the 5' breakpoint implicating a mechanism different to Alu-mediated recombination, responsible for the majority of rearrangements in the BRCA1 gene. Conclusions We conclude that a combination of techniques capable of detecting both single base mutations and small insertions / deletions and large genomic rearrangements is necessary in order to accurately analyze the BRCA1 gene in patients at high risk of carrying a germline mutation as determined by their family history. Furthermore, our results suggest that in those families with strong evidence of linkage to the BRCA1 locus in whom no point mutation has been identified re-examination should be carried out searching specifically for genomic rearrangements.
- Published
- 2004
106. Adriamycin and cis-platinum as first-line treatment in unresectable locally advanced or metastatic adult soft-tissue sarcomas
- Author
-
Michalis V. Karamouzis, Grigorios Iconomou, Theodoros G. Kourelis, Dimitrios Bafaloukos, Dimitrios Dimitropoulos, Paris Kosmidis, E Lampiris, Ekaterini Tsiata, Haralabos P. Kalofonos, and Panagiotis Megas
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Gastroenterology ,Stable Disease ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Adverse effect ,Survival analysis ,Aged ,Chemotherapy ,business.industry ,Sarcoma ,Middle Aged ,medicine.disease ,Survival Analysis ,Surgery ,Radiation therapy ,Regimen ,Oncology ,Doxorubicin ,Toxicity ,Female ,Cisplatin ,business ,Progressive disease - Abstract
Standard chemotherapy in advanced adult soft-tissue sarcomas (STS) has not yet been established. We evaluated the efficacy and toxicity of the combination of adriamycin (ADR) and cis-platinum (CDDP) as first-line treatment in nonoperable locally advanced or metastatic adult STS. Thirty patients were treated with CDDP 100 mg/m2 on day 1 and ADR 75 mg/m2 equally divided on days 1 to 3, every 3 weeks for 6 cycles. Patients were evaluated for response, toxicity, and survival, while resectability of residual disease was also assessed after the third cycle and the end of chemotherapy. No complete response was observed. Five patients (16.7%, 95% CI: 2.5%-31%) achieved partial response, 16 patients (53.3%, 95% CI: 34%-72%) had stable disease and 9 patients (30%, 95% CI: 13%-47%) had progressive disease. The overall median survival was 11.5 months (range, 4-96 months), and the median time to disease progression was 6 months (range, 0-96 months). Furthermore, two patients with PR and six patients with stable disease underwent further surgery followed by radiotherapy in four of them. At present, 5 patients remain free of relapse for 96, 90, 72, 60, and 48 months, respectively. Treatment-related toxicity was acceptable, with moderate myelosuppression and alopecia as the main adverse events. The ADR/CDDP regimen was well tolerated, but it did not achieve a high response rate. However, patients with resectable disease after chemotherapy achieved long-term survival. Further studies are needed to evaluate the role of combined-modality treatments in the management of patients with advanced STS.
- Published
- 2004
107. Advanced NSCLC: new cytostatic agents
- Author
-
Christian Manegold and Paris Kosmidis
- Subjects
Pulmonary and Respiratory Medicine ,Cancer Research ,Epothilones ,Guanine ,Lung Neoplasms ,Organoplatinum Compounds ,medicine.medical_treatment ,Cytostatic agents ,Antineoplastic Agents ,Pemetrexed ,Epothilone ,Irinotecan ,Glutamates ,health services administration ,Carcinoma, Non-Small-Cell Lung ,medicine ,Humans ,neoplasms ,Chemotherapy ,Clinical Trials as Topic ,business.industry ,Thymidylate Synthase ,digestive system diseases ,Oxaliplatin ,stomatognathic diseases ,Oncology ,Lung disease ,Immunology ,Cancer research ,Camptothecin ,Non small cell ,business ,therapeutics ,medicine.drug - Abstract
There are several new cytostatic agents under investigation for the treatment of advanced non-small cell lung cancer either as first or second-line. In this review we will present the current information about oxaliplatin, epothilones, irinotecan and alimta.
- Published
- 2003
108. Contribution of an Anti-CEA Fab' scan in the detection of medullary thyroid cancer
- Author
-
Julia Malamitsi, Savvas Papadopoulos, Dimitrios Linos, Andreas Petounis, and Paris Kosmidis
- Subjects
Pathology ,medicine.medical_specialty ,Lymphatic metastasis ,Organotechnetium Compounds ,Thyroid Gland ,Contrast Media ,Carcinoembryonic antigen ,Antibodies monoclonal ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Radionuclide imaging ,Thyroid Neoplasms ,Radionuclide Imaging ,biology ,business.industry ,Thyroid ,Biopsy, Needle ,Medullary thyroid cancer ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,Carcinoembryonic Antigen ,medicine.anatomical_structure ,Medullary carcinoma ,Carcinoma, Medullary ,Lymphatic Metastasis ,biology.protein ,Female ,business ,Goiter, Nodular - Published
- 2002
109. Basaloid carcinoma, a rare primary lung neoplasm: report of a case and review of the literature
- Author
-
Kosmas H Iliadis, Paris Kosmidis, Panayiotis M Mauroudis, and Christopher N Foroulis
- Subjects
Pulmonary and Respiratory Medicine ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Lung Neoplasms ,business.industry ,Large cell ,Respiratory disease ,Middle Aged ,medicine.disease ,Small-cell carcinoma ,Primary Neoplasm ,Diagnosis, Differential ,Pulmonary Disease, Chronic Obstructive ,Oncology ,Epidermoid carcinoma ,Carcinoma, Non-Small-Cell Lung ,Carcinoma ,Medicine ,Humans ,Neoplasm Invasiveness ,Differential diagnosis ,business ,Lung cancer - Abstract
Basaloid carcinoma of the lung is a rare primary neoplasm, first described in 1992. Basaloid carcinoma is an aggressive subtype of Non small cell lung cancer, with poor 5-year survival, even in stage I and II resected tumors. Differential diagnosis from small cell, Neuroendocrine large cell and poorly differentiated squamous cell carcinoma is difficult to be made. We report a patient with lung basaloid carcinoma, initially diagnosed and treated as small cell carcinoma. Thoracotomy and resection of the tumor following chemotherapy, established the correct diagnosis.
- Published
- 2002
110. First-line combination chemotherapy with mitoxantrone, methotrexate, vincristine and carboplatin (MIMOC) in advanced breast cancer
- Author
-
A. Klinaki, Dimitris Bafaloukos, Ch. Bacoyiannis, N. Milonakis, A. Karabelis, N. Karvounis, D. Daliani, Paris Kosmidis, and George Samonis
- Subjects
Adult ,Oncology ,Cancer Research ,Vincristine ,medicine.medical_specialty ,medicine.medical_treatment ,Phases of clinical research ,Breast Neoplasms ,Carboplatin ,chemistry.chemical_compound ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Prospective Studies ,Aged ,Chemotherapy ,Mitoxantrone ,business.industry ,Cancer ,Combination chemotherapy ,Middle Aged ,Prognosis ,medicine.disease ,Methotrexate ,chemistry ,Female ,business ,medicine.drug - Abstract
51 patients with stage IIIB and IV breast cancer entered a prospective phase II study of combination chemotherapy that consisted of mitoxantrone (8 mg/m2) day 1, methotrexate (25 mg/m2) day 1, vincristine (1 mg/m2) day 2 and carboplatin (250 mg/m2) day 2 (MIMOC) given in a 3-weekly schedule. None had received prior chemotherapy for metastatic disease, although 16 patients were given adjuvant chemotherapy. Objective response to treatment was seen in 29 of 48 patients analysed for response (60%) with 8 complete responses (CR). 7 out of 8 patients with stage IIIB disease responded, 2 of them completely. Responses were seen in all sites but the best results were achieved in lung metastases with 50% CR. The median duration of response was 8 months and the median time to disease progression was 12 months. The main toxicity was nausea and vomiting which was severe in 20% of the patients. Other toxicities were mild. MIMOC was administered on an out-patient basis and appears to be effective as first-line treatment in advanced breast cancer.
- Published
- 1993
111. mRNA expression patterns of growth and survival related genes for identification of distinct prognostic groups in advanced pancreatic cancer patients treated with chemotherapy and an EGFR inhibitor
- Author
-
Epaminondas Samantas, Elpida Charalambous, Vassiliki Kotoula, Paris Kosmidis, Christos Agalianos, George Pentheroudakis, Chrysoula Gkakou, Dimitrios G. Pectasides, Konstantine T. Kalogeras, George Papaxoinis, Christos Dervenis, George Fountzilas, and Zoi Alexopoulou
- Subjects
Oncology ,Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Mrna expression ,medicine.disease ,Pancreatic cancer ,Internal medicine ,medicine ,In patient ,Identification (biology) ,business ,Gene ,EGFR inhibitors - Abstract
e15259 Background: The aim of the study was to examine the mRNA expression pattern of growth and survival related genes and their prognostic significance in patients with advanced pancreatic cancer...
- Published
- 2014
112. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group
- Author
-
A. Anagnostopoulos, Ioannis M. Varkarakis, Charalambos Deliveliotis, Christos Papadimitriou, Meletios A. Dimopoulos, Aristotelis Bamias, C. Bakoyannis, Andreas A. Giannopoulos, Lia A. Moulopoulos, G. Fountzilas, Anastasios Zervas, Zacharias Kyriakakis, Paris Kosmidis, Gerassimos Aravantinos, D. Pantazopoulos, V. Georgoulias, and A. Karayannis
- Subjects
Male ,medicine.medical_treatment ,Phases of clinical research ,cisplatin ,Docetaxel ,Gastroenterology ,Severity of Illness Index ,transitional-cell-carcinoma ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,docetaxel ,Aged, 80 and over ,Greece ,Remission Induction ,Combination chemotherapy ,Hematology ,trial ,Middle Aged ,Chemotherapy regimen ,Survival Rate ,Treatment Outcome ,Oncology ,urothelial cancer ,Lymphatic Metastasis ,Female ,Taxoids ,medicine.drug ,Adult ,medicine.medical_specialty ,Urologic Neoplasms ,Paclitaxel ,Neutropenia ,doxorubicin ,methotrexate ,Internal medicine ,vinblastine ,cancer ,Humans ,Survival rate ,Aged ,Chemotherapy ,Carcinoma, Transitional Cell ,business.industry ,agent ,medicine.disease ,Surgery ,Urinary Bladder Neoplasms ,Linear Models ,Cisplatin ,Urothelium ,business ,Progressive disease ,Follow-Up Studies - Abstract
Purpose: Both docetaxel and cisplatin have moderate activity in patients with advanced urothelial cancer. We performed a multicenter phase II study in order to assess the efficacy and toxicity of the combination of these two agents in patients with advanced carcinoma of the urothelium. Patients and methods: Sixty-six patients not amenable to curative surgery or irradiation were enrolled onto this cooperative group study and treated on an outpatient basis with docetaxel 75 mg/m(2) followed by cisplatin 75 mg/m(2), both administered intravenously. Granulocyte-colony stimulating factor was administered subcutaneously at a dose of 5 mu g/kg daily from day 5 until resolution of neutropenia. The chemotherapy was administered every three weeks for a maximum of six courses in patients without evidence of progressive disease. Results: Thirty-four of sixty-six patients (52%, 95% confidence interval 40%-64%) demonstrated objective responses, with eight achieving clinical complete responses and twenty-six partial responses. A multivariate logistic regression analysis indicated that the patients most likely to respond were those without lung metastasis and without weight loss before treatment. The median duration of response was 6.1 months and the median times to progression and survival for all patients were 5 and 8 months, respectively. Absence of anemia, of liver metastases and of weight loss correlated with longer survival. Grade greater than or equal to 3 toxicities included granulocytopenia in 33% of patients, anemia in 14%, diarrhea in 13% and emesis in 7% of patients. Conclusion: The combination of docetaxel and cisplatin appeared relatively well tolerated and moderately active in patients with advanced urothelial cancer. The patients most likely to benefit were those without weight loss and without lung or liver metastases. Annals of Oncology
- Published
- 2000
113. Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study
- Author
-
Gerasimos Aravantinos, George Fountzilas, D. Tsavdaridis, Paris Kosmidis, Thomas Makatsoris, Pavlos Papakostas, Dimitrios Pectasides, Ioannis Xanthakis, G. Klouvas, Helen Gogas, and Haralabos P. Kalofonos
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Phases of clinical research ,Docetaxel ,Neutropenia ,Filgrastim ,Adenocarcinoma ,Severity of Illness Index ,Drug Administration Schedule ,Statistics, Nonparametric ,Carboplatin ,chemistry.chemical_compound ,Adjuvants, Immunologic ,Stomach Neoplasms ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Granulocyte Colony-Stimulating Factor ,medicine ,Humans ,Aged ,Epirubicin ,Chemotherapy ,business.industry ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Hematologic Diseases ,Survival Analysis ,Regimen ,Treatment Outcome ,chemistry ,Female ,Taxoids ,business ,medicine.drug - Abstract
Chemotherapy is an established modality in the management of patients with advanced gastric cancer but the optimal regimen has not been defined yet. Platinum and the anthracyclines and more recently docetaxel have shown activity in this tumor. The primary objective of this phase II study was to assess the efficacy and safety of an intensified regimen of weekly docetaxel/epirubicin/carboplatin (DECb) with growth factor support in previously untreated patients with advanced gastric cancer. A total of 72 patients with measurable disease received docetaxel at a dose of 30 mg/m2, epirubicin at a dose of 30 mg/m2 and carboplatin to a target area under the curve (AUC) of 2, every week for 6 consecutive weeks followed by 2 weeks’ rest, with filgrastim support. Analysis was performed on an intention to treat basis. The main toxicity was hematologic with grade 3/4 neutropenia occurring in 35% of the patients. Other grade 3/4 toxicities included anemia (7%), thrombocytopenia (14%) and leucopenia (26%). The relative dose intensity of docetaxel and epirubicin was 62%. The overall response rate was 21%, the median time to tumor progression was 4.1 months and the median survival 7.3 months. Intensified weekly treatment with DECb has modest activity in the treatment of advanced gastric cancer. Myelotoxicity limits adequate drug delivery.
- Published
- 1999
114. Salvage Chemotherapy for Breast Cancer Patients Treated with Adjuvant Adriamycin-Containing Regimen
- Author
-
D. Kondylis, Paris Kosmidis, and Byron Lissaios
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Salvage treatment ,Breast Neoplasms ,Gastroenterology ,Group A ,Drug Administration Schedule ,Group B ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,In patient ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Vinblastine ,Survival Rate ,Regimen ,Doxorubicin ,Female ,business ,Adjuvant ,medicine.drug - Abstract
Purpose of this study was to evaluate the efficacy of salvage chemotherapy given to women with breast cancer in relapse who had in the past received adjuvant treatment including adriamycin. Fourty-nine evaluable patients had an adjuvant chemotherapy with CMFAV in 6 or 12 cycles. On relapse these patients received either adriamycin 40 mg/m2, mitomycin 8 mg/m2 and vinblastine 6 mg/m2 (group A) or dibromodulcitol 500 mg, mitomycin 8 mg/m2 and vinblastine 6 mg/m2 (group B). In Group A, 22 patients with a mean age of 49.2 years relapsed 14 months on average after the end of adjuvant treatment. In 11 of them the main site of relapse was visceral. In group B, 27 patients with a mean age 49.5 years relapsed 6.5 months on average after the end of adjuvant treatment. In 15 of them the main site of relapse was visceral. According to the disease-free interval (DFI), in group A with DFI less than 12 months 3 patients (23%) responded partially whereas in patients with DFI longer than 12 months 4 patients (44.4%) had a partial response. In group B with DFI less than 12 months 4 patients (21%) responded partially, whereas 2 (25%) responded with DFI longer than 12 months. We conclude that salvage chemotherapy in this group of patients with an adriamycin-containing regimen is superior to a non-adriamycin regimen only if the DFI is longer than 12 months.
- Published
- 1990
115. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group
- Author
-
R Lewensohn, H Szpirglas, J Oliveira, H Jacob, M Gore, K Robbins, Dirk Schrijvers, U Jiminez, C Arvay, P Langecker, J Johnson, E Vokes, E Cvitkovic, J Schüller, Paris Kosmidis, and A Riviere
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Interferon alpha-2 ,Metastasis ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Interferon alfa ,Aged ,Cisplatin ,Chemotherapy ,Performance status ,business.industry ,Head and neck cancer ,Remission Induction ,Interferon-alpha ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,Survival Analysis ,Recombinant Proteins ,Surgery ,Fluorouracil ,Head and Neck Neoplasms ,Female ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
PURPOSE In preclinical experiments, interferon alfa modulates the anticancer activity of fluorouracil (5-FU) and cisplatin (CDDP). To test this effect clinically in patients with recurrent or metastatic head and neck cancer (RMHNC), a multicenter randomized controlled trial with CDDP and 5-FU with or without interferon alfa-2b (IFNalpha) was performed. PATIENTS AND METHODS Eligible patients had histologically confirmed RMHNC; a good performance status; measurable disease; adequate bone marrow, hepatic, and renal function; no prior chemotherapy for recurrent or metastatic disease; only one chemotherapy regimen administered with previous local therapy; and a treatment-free interval of at least 3 months following previous local therapy. Patients were randomized and stratified according to treatment center, and prior radiotherapy and chemotherapy. The treatment regimen consisted of CDDP 100 mg/m2 on day 1 and 5-FU 1,000 mg/m2/d by continuous infusion for 96 hours (days 1 to 4), without (arm A) or with (arm B) IFNg alpha 3 x 10(6) U/d subcutaneously on days 1 to 5. Cycles were repeated every 21 days. RESULTS One hundred twenty-two patients were entered on each arm. The response rate (RR) was similar in both arms (arm A: complete response [CR] 10.7%, partial response [PR] 36.4%; arm B: CR 6.8%, PR 31.6%) (.70 < P < .50). There was no difference in median survival between the two arms (arm A 6.3 months v arm B 6.0 months; P = .49). Anorexia, fever, leukopenia, and thrombocytopenia grade III to IV were significantly more frequent in the IFNalpha arm. CONCLUSION Modulation of CDDP and 5-FU with IFNalpha as used in this study does not improve the RR or the median survival in patients with RMHNC. Patients on both study arms had a poor prognosis, which indicates the need for novel therapies.
- Published
- 1998
116. Long-term survival data and prognostic factors of a complete response to chemotherapy in patients with head and neck cancer treated with platinum-based induction chemotherapy: a Hellenic Co-operative oncology Group study
- Author
-
George Fountzilas, Epaminontas Samantas, P. Makrantonakis, Vasilios Avramidis, Anna Kalogera-Fountzila, Paris Kosmidis, Angelos Nikolaou, Charalambos Bacoyiannis, J. Daniilidis, and Dimosthenis Skarlos
- Subjects
Oncology ,Adult ,Male ,Cancer Research ,Prognostic variable ,medicine.medical_specialty ,Time Factors ,Adolescent ,medicine.medical_treatment ,Platinum Compounds ,chemistry.chemical_compound ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Stage (cooking) ,Aged ,Cisplatin ,Chemotherapy ,Greece ,business.industry ,Head and neck cancer ,Remission Induction ,Induction chemotherapy ,Middle Aged ,medicine.disease ,Prognosis ,Survival Analysis ,Carboplatin ,Radiation therapy ,Logistic Models ,chemistry ,Head and Neck Neoplasms ,Pediatrics, Perinatology and Child Health ,Disease Progression ,Female ,business ,medicine.drug - Abstract
A group of 154 patients with locally advanced head and neck cancer, treated with platinum-based induction chemotherapy, were followed up for 5 years and several pretreatment characteristics were analyzed for possible correlation to a complete response (CR) to chemotherapy, time to progression (TTP) and overall survival (OS). Clinical stage (p = 0.0125) were selected as important prognostic factors for CR by step-wise logistic regression. We also identified response to chemotherapy (p = 0.0120), age (p = 0.0066), clinical stage (p = 0.0363), N stage (p = 0.0028), and tumor grade (p = 0.0101) as significant prognostic variables for TTP. Response to chemotherapy (p < 0.0001) and age (p = 0.0017) were found also significant for OS. These long-term prognostic factors which retain their prognostic significance after several years of follow-up could be helpful in the design of future trials in this patient population. Med. Pediatr. Oncol. 28:401–410, 1997. © 1997 Wiley-Liss, Inc.
- Published
- 1997
117. A phase II study of paclitaxel in platinum pretreated ovarian cancer. A Hellenic Cooperative Oncology Group study
- Author
-
Paris Kosmidis, A. Athanassiades, Dimitris Bafaloukos, Gerassimos Aravantinos, S. Karpathios, D.V. Skarlos, George Fountzilas, and T. Giannakakis
- Subjects
Adult ,Cancer Research ,medicine.medical_specialty ,Paclitaxel ,medicine.medical_treatment ,Phases of clinical research ,Platinum Compounds ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,medicine ,Carcinoma ,Humans ,Aged ,Cisplatin ,Ovarian Neoplasms ,Chemotherapy ,Performance status ,business.industry ,Middle Aged ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Surgery ,Survival Rate ,Regimen ,Treatment Outcome ,Oncology ,chemistry ,Drug Resistance, Neoplasm ,Patient Compliance ,Female ,Ovarian cancer ,business ,medicine.drug - Abstract
Paclitaxel was administered at a dose of 175 mg/m2 in a 3-hour infusion every 3 weeks in platinum pretreated patients with ovarian cancer. 51 patients with a median age of 57 years entered the study. 33 (65%) presented with stage III and 18 (35%) with stage IV disease. 39 patients (76%) were previously treated with only one and 12 (24%) with two regimens. The median interval from the last previous chemotherapy was 4 months (range, 1–65). Ninety-eight per cent of the planned dose of paclitaxel was actually delivered. Overall and complete response rate was 26% ( 13 51 ) and 16% ( 8 51 ), respectively. All complete responses were observed among patients previously treated with only one regimen. Median time to progression was 10.26 months (range, 4.9–25.2+) and median survival 15.6 months (range, 1.3–27.1+). Factors influencing survival were performance status and the number of previous regimens.
- Published
- 1997
118. Evaluation of the prognostic/predictive role of tumor EGFR and KRAS mutations in Greek metastatic non-small cell lung cancer patients treated with first-line chemotherapy
- Author
-
Vassiliki Kotoula, Georgios Lazaridis, Vasilios Karavasilis, Dimitris Bafaloukos, George Fountzilas, Epaminontas Samantas, Anastasia G Eleftheraki, Sotiris Lakis, Dimitrios G. Pectasides, Emily Daskalaki, Elpida Charalambous, Paris Kosmidis, and Helena Linardou
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Histology ,medicine.disease_cause ,medicine.disease ,digestive system diseases ,respiratory tract diseases ,Internal medicine ,Genotype ,medicine ,Adenocarcinoma ,Non small cell ,KRAS ,business ,Lung cancer ,neoplasms ,Tyrosine kinase - Abstract
e19048 Background: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC). Little is known about the prognostic/predictive role of KRAS in advanced NSCLC, with conflicting results among small studies. Recent evidence showed that KRAS mutations could predict for worse outcome in patients treated with platinum-based adjuvant chemotherapy. Methods: KRAS and EGFR genotypes were evaluated in 414 NSCLC patients with available clinical data, diagnosed from March 2000 to December 2012 (tissue blocks from the HeCOG tumor repository). KRAS and EGFR mutations were associated with clinicopathological parameters (mutated vs. wild-type). Outcome comparisons were performed in 214 metastatic patients with treatment data available, following 1st-line chemotherapy without tyrosine kinase inhibitors. Results: The majority of the patients were male (80%), current smokers (53%), with adenocarcinoma (AC) histology (65%). EGFR mutations were found in 10% and KRAS mutations in 17% of all histological types, while in AC they were 14% and 21%, respectively. Most EGFR mutations were classical (79%), while most common KRAS mutations were p.G12C (39%), p.G12D (30%) and p.G12V (15%). Two tumors had concurrent EGFR and KRAS mutations. EGFR mutations were significantly associated with female gender, AC histology and non-smoking status, as previously described. KRAS mutations were associated with AC histology and younger age (st-line treatment decreases the risk of death.
- Published
- 2013
119. Two cycles of carboplatin as adjuvant therapy in stage I seminoma: 8-year experience by the Hellenic Co-operative Oncology Group (HECOG)
- Author
-
Georgios Rigakos, Paris Kosmidis, K. Stravodimos, Aristotelis Bamias, Eleni Efstathiou, Vasilios Karavasilis, Maria Lykka, Eleni Galani, Thomas Makatsoris, G. Klouvas, Athanasios Papatsoris, Ioanis Adamakis, George Fountzilas, Meletios A. Dimopoulos, Konstantinos Koutsoukos, Michael Liontos, Anna Andreadou, Angelos Koutras, Christos Alamanis, and Michael Chrisofos
- Subjects
Co operative ,Oncology ,Cisplatin ,Cancer Research ,medicine.medical_specialty ,Adjuvant chemotherapy ,business.industry ,Carboplatin ,Surgery ,chemistry.chemical_compound ,Stage I Seminoma ,chemistry ,Internal medicine ,medicine ,Adjuvant therapy ,Stage I Testicular Seminoma ,business ,Etoposide ,medicine.drug - Abstract
4558 Background: Adjuvant chemotherapy is used in stage I testicular seminoma. We have reported a risk-adapted strategy of 2 cycles of cisplatin/etoposide (EP) in 64 patients with age < 34 and/or tumor diameter > 4cm) (Bamias et al, Urology 2007), resulting in no relapses over a median follow up of 5 years. Following the establishment of adjuvant carboplatin as a standard, we adopted this treatment for all patients with stage I seminoma. We report our 8-year experience and compare these results with our previous EP strategy. Methods: Patients with stage I seminoma, treated with 2 cycles of carboplatin AUC 6 and a minimum follow up of 1 year after chemotherapy were selected. All patients consented for the use of their medical information and the analysis was approved by the centers involved. Survival functions were presented using Kaplan-Meier curves. The log-rank test was used to test for survival differences across different categories. Results: 137 patients (Median age: 34; Age4cm: 42%; rete testis invasion: 24%), treated between 11/2003-12/2011 were selected. During a median follow up of 4 years, there were 5 relapses (5-y relapse rate [RR]: 97% [SE: 2%]): retroperitoneal lymph nodes (n=4) and isolated brain (n=1). All patients with relapse had tumor diameter > 4cm and/or age < 34. No relapse was associated with rete testis invasion. Patients with at least 1 of the above risk factors (n=94) had a significantly higher relapse rate compared with a similar population (n=64) treated with 2 cycles of adjuvant EP: 5-y RR was 95% (SE: 2%) vs.100% (SE 0%), (p=0.033). All relapsed patients were treated with BEP chemotherapy and are currently alive with no evidence of relapse. Neutropenia and nausea/vomiting were less frequent with carboplatin than with EP (11% vs. 36% and 15% vs. 65%). Conclusions: Our analysis confirms the association of age and tumor diameter with relapse in stage I seminoma treated with adjuvant carboplatin. Although adjuvant carboplatin in patients with age 4 cm is associated with higher RR than EP, the prognosis of these patients is excellent with salvage chemotherapy and, therefore, the use of less toxic treatment is justified.
- Published
- 2013
120. Quality of life as a new end point
- Author
-
Paris Kosmidis
- Subjects
Pulmonary and Respiratory Medicine ,Gerontology ,medicine.medical_specialty ,End point ,Lung Neoplasms ,business.industry ,Critical Care and Intensive Care Medicine ,humanities ,Palliative Therapy ,Treatment Outcome ,Quality of life ,Carcinoma, Non-Small-Cell Lung ,Physical therapy ,Quality of Life ,Medicine ,Health Status Indicators ,Humans ,Non small cell ,Cardiology and Cardiovascular Medicine ,business - Abstract
Quality of life (QOL) is a relatively new clinical end point that is particularly relevant to the typically palliative therapy for non-small cell lung cancer. Patients' assessments of their QOL are shown to differ from their physicians', emphasizing the subjective nature of QOL. A number of relevant instruments and assessment techniques are employed. Results from a study using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 instrument before and during chemotherapy are presented. Some parameters improved while others did not, preventing a simple interpretation. There are arguments for compiling indexes of QOL while retaining measures for individual parameters and a desire for the consistent international use of an instrument such as the EORTC questionnaire.
- Published
- 1996
121. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem
- Author
-
Nicolas J. Lygidakis, J. Parissis, E. Kyparidou, N. Ziras, and Paris Kosmidis
- Subjects
Oncology ,Male ,endocrine system ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Mitomycin ,Immunology ,Leucovorin ,Pilot Projects ,Liver transplantation ,Drug Administration Schedule ,Resection ,Carboplatin ,Interferon-gamma ,Necrosis ,Text mining ,Virology ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Overall survival ,Humans ,Infusions, Intra-Arterial ,Stage (cooking) ,Aged ,Epirubicin ,Chemotherapy ,business.industry ,Liver Neoplasms ,Cell Biology ,Immunotherapy ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,digestive system diseases ,Surgery ,Survival Rate ,Liver ,Hepatocellular carcinoma ,Interleukin-2 ,Female ,Fluorouracil ,alpha-Fetoproteins ,business ,Spleen ,Tomography, Emission-Computed - Abstract
The prognosis for patients with advanced (stage III and IV) hepatocellular carcinoma (HCC) remains poor. Liver resection and liver transplantation have limited effects on overall survival. Our study was carried out to assess a novel therapeutic approach, which includes transarterial locoregional chemotherapy and in vivo locoregional dual immunostimulation, in patients with unresectable HCC. A group of 20 patients with stage III and IV hepatocellular carcinoma had 10 courses (once per day) of transarterial targeted locoregional immunotherapy with interferon-gamma (IFN-gamma) and interleukin-2 (IL-2), emulsified in a Lipiodol-Urografin mixture. The target organs were the spleen and the liver tumor itself. One course of intrahepatic locoregional targeting transarterial chemotherapy was given 10 days after completion of immunotherapy (mitomycin C, carboplatin, Farmorubicin, Leucovorin, 5-fluorouracil, and IFN-gamma). This was followed after 2 months by another course of transarterial targeted locoregional immunotherapy-chemotherapy. All patients survived the operation and had a mean survival time of 18 months (4-22 months). There was a decrease in the tumor size of 14 of the 20 patients. Serum alpha-fetoprotein (AFP) levels declined in 14 patients, reaching normal levels in 12 patients. These preliminary results indicate that combined locoregional immunotherapy-chemotherapy is a promising therapeutic approach in patients suffering from advanced nonresectable HCC and merits further evaluation.
- Published
- 1995
122. Ondansetron versus metoclopramide as antiemetic treatment during cisplatin-based chemotherapy. A prospective study with special regard to regard to electrolyte imbalance
- Author
-
Gavrilos Charalambidis, Paris Kosmidis, Nicolas Ganas, Athanasios Karabellis, Margarita Pagou, N. Mylonakis, Dimitris Tsikalakis, Nikoleta Benou, and Nicolas Tsavaris
- Subjects
Adult ,Male ,Metoclopramide ,medicine.drug_class ,medicine.medical_treatment ,Water-Electrolyte Imbalance ,Ondansetron ,Extrapyramidal symptoms ,Neoplasms ,medicine ,Antiemetic ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Aged ,Cisplatin ,Chemotherapy ,business.industry ,Nausea ,Hematology ,General Medicine ,Middle Aged ,Oncology ,Anesthesia ,Chemoprophylaxis ,Vomiting ,Drug Therapy, Combination ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Cancer patients selected for cisplatin-based chemotherapy were randomly divided into two groups (42 patients in each) which received either metoclopramide or ondansetron as antiemetics. Metoclopramide was given i.v. with 5 doses of 2 mg/kg starting 30 min before the cisplatin infusion and continued with one dose every 3 h. Ondansetron was given with a first injection of 8 mg i.v. 30 min before the cisplatin infusion; the patients were given 8 mg orally 5 and 10 h after the cisplatin infusion followed by 8 mg x 3 during the next two days. In the present study ondansetron was superior to metoclopramide concerning antiemetic efficacy and gave also less side-effects as diarrhea, dizziness, extrapyramidal symptoms and electrolyte imbalance (sodium, potassium, magnesium, phosphorous) during the first 24 h following the cisplatin infusion.
- Published
- 1995
123. Comparison of ondansentron (GR 38032F) versus ondansentron plus alprazolam as antiemetic prophylaxis during cisplatin-containing chemotherapy
- Author
-
C. Bacoyiannis, N. Mylonakis, Margarita Pagou, Paris Kosmidis, A. Karabelis, Gavrilos Charalambidis, and Nicolas Tsavaris
- Subjects
Adult ,Male ,Cancer Research ,Randomization ,Nausea ,medicine.drug_class ,Vomiting ,medicine.medical_treatment ,Group B ,law.invention ,Randomized controlled trial ,law ,Neoplasms ,Medicine ,Antiemetic ,Humans ,Aged ,Chemotherapy ,Alprazolam ,business.industry ,Middle Aged ,Ondansetron ,Oncology ,Anesthesia ,Drug Therapy, Combination ,Female ,medicine.symptom ,Cisplatin ,business ,medicine.drug - Abstract
The purpose of our study was to evaluate the effectiveness of alprazolam (APZ) as an adjuvant drug to ondansentron against cisplatin-induced emesis. All patients received CDDP 100 mg/m2, and had previously received chemotherapy. We established two groups of patients randomly: Group A patients received 5-HT3 alone, and Group B received 5-HT3 and APZ. The drugs were administered as follows: 5-HT3 was given at a dose of 1 ampule 8 mg in 100 ml N/S in 10 minutes i.v. infusion before the infusion of CDDP. We continued with 1 tablet 8 mg in the afternoon and 1 before sleeping the first day; for the next two days, patients received 3 tablets 8 mg/day. APZ was given in tablets of 0.25 mg 60 minutes before CDDP infusion and then with the second and third dose of 5-HT3. We did not find significant differences in clinical parameters and factors, especially anxiety, that influenced vomiting between the examined groups. The mean number of vomiting episodes without gastric content (4.76 episodes) and the mean duration of nausea (195 minutes), were greater in Group A than in Group B (1.39 episodes, p < .0001; 91 minutes, p < .049). Differences also were found in the mean number of vomiting episodes with gastric content between the examined groups (A: 1.97; B: 1.09; p < .135). The intense of nausea and vomiting according to WHO classification was greater in Group A (grade 0, p < .004; grade 2, p < .020) than in Group B. Patients of Group B had fewer problems with appetite (p < .027), and more intense sedative effect (grade 0 [p < .001], 1 [0.027], 2 [0.022]) than patients of Group A. In conclusion APZ improved the antiemetic efficacy of ondansentron in cisplatin-induced emesis.
- Published
- 1994
124. Radiation therapy and concurrent cisplatin administration in locally advanced head and neck cancer. A Hellenic Co-operative Oncology Group study
- Author
-
Kasi S. Sridhar, J. Daniilidis, Dimosthenis Skarlos, Maria Sinodinou, Spyros Papaspyrou, Epaminontas Samantas, Constantinos Banis, Angelos Nikolaou, H. Bacoyiannis, Panayiotis Pantelakos, Paris Kosmidis, John Tzitzikas, George Fountzilas, Anna Kalogera-Fountzila, and P. Makrantonakis
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Nephrotoxicity ,Weight loss ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Stomatitis ,Aged ,Cisplatin ,business.industry ,Head and neck cancer ,Remission Induction ,Radiotherapy Dosage ,Hematology ,General Medicine ,Middle Aged ,medicine.disease ,Dysphagia ,Survival Analysis ,Surgery ,Radiation therapy ,Oncology ,Chemotherapy, Adjuvant ,Head and Neck Neoplasms ,Vomiting ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
In an attempt to improve local control of locally advanced head and neck cancer, radiation therapy was combined with cisplatin. Forty-eight patients entered into this study. All patients were irradiated with a 60Co unit and according to the protocol they should receive 70 Gy in the tumor area and 45 Gy in the rest of neck. Cisplatin was administered at a dose of 100 mg/m2 on days 2, 22 and 42. Thirty-seven (80%) patients received the total radiation dose as initially planned. Thirty-four (72%) patients achieved complete and 5 (10%) partial response. Grade 3-4 toxicities included vomiting (14%), stomatitis (4%), diarrhea (2%), myelotoxicity (14%), hoarseness (4%), dysphagia (30%), weight loss (32%), nephrotoxicity (4%) and dermatitis (2%). After a median follow-up of 26 (range, 18-33) months, 16 patients have died. Among the 35 complete responders 6 later on relapsed. Median relapse-free survival has not yet been reached. Combined radiation therapy and cisplatin appears to be a highly active treatment in patients with advanced head and neck cancer as far as primary locoregional response is concerned.
- Published
- 1994
125. Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases
- Author
-
George Fountzilas, Athanasios Dimitriadis, Paris Kosmidis, P. Makrantonakis, Kasi S. Sridhar, Thomas Zaramboukas, A. Nicolaou, J. Daniilidis, A. Vritsios, Anna Kalogera-Fountzila, K. Sombolos, C. Themelis, A. Tourkantonis, and K. Banis
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Leucovorin ,Adenocarcinoma ,Gastroenterology ,Carboplatin ,chemistry.chemical_compound ,Bleomycin ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Aged ,Retrospective Studies ,Cisplatin ,Chemotherapy ,business.industry ,Induction chemotherapy ,Combination chemotherapy ,Nasopharyngeal Neoplasms ,Hematology ,General Medicine ,Middle Aged ,Combined Modality Therapy ,Surgery ,Radiation therapy ,Regimen ,Methotrexate ,Oncology ,chemistry ,Carcinoma, Squamous Cell ,Female ,Fluorouracil ,business ,medicine.drug - Abstract
A retrospective analysis was performed of 39 patients with locally advanced nasopharyngeal cancer treated with combined chemotherapy and radiation therapy during the last five years at our departments. There were 26 men and 13 women with median age 55 (24-75) years. Histology was squamous cell carcinoma in 6 patients and undifferentiated carcinoma in the remaining 33 patients. Induction chemotherapy consisted of either regimen A (cisplatin 100 mg/m2 day 1, 5-FU 1,000 mg/m2 days 2-6 as continuous infusion, bleomycin 15 mg days 15 and 29 i.m., mitomycin 4 mg/m2 day 22 and hydroxyurea 1,000 mg/m2 daily days 23-27) or regimen B (carboplatin 300 mg/m2 day 1, 5-FU 1,000 mg/m2 days 1-5 as continuous infusion and methotrexate 1.2 g/m2 day 14 with leucovorin rescue). After completion of induction chemotherapy 13 patients (33%) had complete remission (CR) and 19 (49%) partial remission (PR). The CR rate was increased after radiation therapy to 72%. Survival rates were 88% at 12 and 78% at 24 months. Median time to progression was 29.5 months. In conclusion, induction chemotherapy with a platinum-based regimen followed by radiation therapy achieved a high rate of local control. If the treatment also prolongs survival must, however, be studied by randomized trials.
- Published
- 1991
126. Management of bone metastases from lung cancer: Consensus recommendations from an international panel
- Author
-
David S. Ettinger, Christian Manegold, Paris Kosmidis, Peter Harper, Kristiaan Nackaerts, and Corey J. Langer
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Structural integrity ,Radiology ,Lung cancer ,medicine.disease ,business - Abstract
19080 Background: In approximately 30% to 40% of patients with advanced lung cancer (LC), bone metastases (mets) develop that undermine the structural integrity of the affected bone. With therapeut...
- Published
- 2008
127. Predicting Metastatic Behaviour in Lung Adenocarcinoma
- Author
-
I. Boukovinas and Paris Kosmidis
- Subjects
Oncology ,medicine.medical_specialty ,Lung ,medicine.anatomical_structure ,business.industry ,Internal medicine ,medicine ,Adenocarcinoma ,Hematology ,medicine.disease ,business - Published
- 2008
128. Predicting Metastatic Behavior in Lung Adenocarcinoma
- Author
-
Paris Kosmidis and I. Boukovinas
- Subjects
Oncology ,medicine.medical_specialty ,Lung ,medicine.anatomical_structure ,business.industry ,Internal medicine ,medicine ,Adenocarcinoma ,medicine.disease ,business - Published
- 2008
129. E37. Non-platinum regimens for advanced disease: Patient selection based on subhistologies of NSCLC
- Author
-
Paris Kosmidis
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Advanced disease ,Non platinum ,business ,Selection (genetic algorithm) - Published
- 2005
130. P-685 Prospective data from the european cancer anaemia survey (ECAS): Focus on patients with lung cancer
- Author
-
Maciej Krzakowski and Paris Kosmidis
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Focus (computing) ,business.industry ,Prospective data ,Cancer ,medicine.disease ,Internal medicine ,Epidemiology of cancer ,medicine ,Lung cancer ,business - Published
- 2003
131. First International Workshop on Lung Cancer: Prognostic and predictive factors
- Author
-
Paris Kosmidis
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,Lung cancer ,medicine.disease ,business - Published
- 2000
132. Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer.
- Author
-
Pavlos Papakostas, Haralabos Kalofonos, Ioannis Xanthakis, Dimitrios Tsavdaridis, Gerasimos Aravantinos, Helen Gogas, George Klouvas, Paris Kosmidis, Dimitrios Pectasides, and George Fountzilas
- Abstract
Abstract Chemotherapy is an established modality in the management of patients with advanced gastric cancer but the optimal regimen has not been defined yet. Platinum and the anthracyclines and more recently docetaxel have shown activity in this tumor. The primary objective of this phase II study was to assess the efficacy and safety of an intensified regimen of weekly docetaxel/epirubicin/carboplatin (DECb) with growth factor support in previously untreated patients with advanced gastric cancer. A total of 72 patients with measurable disease received docetaxel at a dose of 30 mg/m2, epirubicin at a dose of 30 mg/m2 and carboplatin to a target area under the curve (AUC) of 2, every week for 6 consecutive weeks followed by 2 weeks’ rest, with filgrastim support. Analysis was performed on an intention to treat basis. The main toxicity was hematologic with grade 3/4 neutropenia occurring in 35% of the patients. Other grade 3/4 toxicities included anemia (7%), thrombocytopenia (14%) and leucopenia (26%). The relative dose intensity of docetaxel and epirubicin was 62%. The overall response rate was 21%, the median time to tumor progression was 4.1 months and the median survival 7.3 months. Intensified weekly treatment with DECb has modest activity in the treatment of advanced gastric cancer. Myelotoxicity limits adequate drug delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2007
133. Interferon-alpha (IFN-a) in combination with carboplatin (C) vinblastine (V) and bleomycin (B) in metastatic malignant melanoma (M.M.)
- Author
-
Paris Kosmidis, N. Pavlidis, T. Giannakakis, D.V. Skarlos, Dimitris Bafaloukos, G. Klouvas, and G. Fountzilas
- Subjects
Cancer Research ,business.industry ,Alpha interferon ,Bleomycin ,Carboplatin ,Vinblastine ,chemistry.chemical_compound ,Metastatic malignant melanoma ,Oncology ,chemistry ,medicine ,Cancer research ,business ,medicine.drug - Published
- 1993
134. Intraperitoneal administration (I.P.) of interferon-a (IFN-a) in patients with ovarian CA, in clinical complete remission (cCR) following chemotherapy with high doses of carboplatin (C) and haemopoetic growth factors (H.G.F.)
- Author
-
P. Markantonakis, D.V. Skarlos, Paris Kosmidis, T. Giannakakis, G. Fountzilas, and Dimitris Bafaloukos
- Subjects
Cancer Research ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Ovarian Ca ,Complete remission ,Pharmacology ,Carboplatin ,chemistry.chemical_compound ,Oncology ,chemistry ,Interferon ,High doses ,Medicine ,In patient ,business ,medicine.drug - Published
- 1993
135. Fluorouracil (5-FU) and follinic acid (FA) with or without a2b-interferon (IFN) in advanced colorectal cancer (ACC). A prospective randomized trial
- Author
-
D. Theocharis, N. Pavlidis, G. Fountzilas, Paris Kosmidis, D.V. Skarlos, M. Beer, E. Briasoulis, N. Tsavaris, and D. Samanta
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,law.invention ,Advanced colorectal cancer ,Randomized controlled trial ,law ,Interferon ,Fluorouracil ,Internal medicine ,Medicine ,business ,medicine.drug - Published
- 1993
136. Clinical evaluation of common serum tumor markers (TM) in patients (PTS) with bladder carcinoma (BC)
- Author
-
Paris Kosmidis, N. Karvounis, Dimitris Bafaloukos, Ch. Bacoyiannis, and N. Tentolouris
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,Carcinoma ,Medicine ,In patient ,business ,medicine.disease ,Clinical evaluation - Published
- 1993
137. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
- Author
-
Epaminondas Samantas, Helena Linardou, Dimitrios Bafaloukos, Athanasios M. Dimopoulos, Christos Papadimitriou, Aristotelis Bamias, Pavlos Papakostas, Thomas Makatsoris, Gerasimos Aravantinos, Haralabos P. Kalofonos, Christos Christodoulou, Eleni Timotheadou, Evangelos Briasoulis, Dimitrios Pectasides, George Fountzilas, and Paris Kosmidis
- Subjects
Adult ,medicine.medical_specialty ,Paclitaxel ,Paclitaxel/administration & dosage/adverse effects ,medicine.medical_treatment ,Carboplatin/administration & dosage/adverse effects ,Ovarian Neoplasms/diagnosis/*drug therapy ,lcsh:Medicine ,Phases of clinical research ,Kaplan-Meier Estimate ,Neutropenia ,Gastroenterology ,Doxorubicin/administration & dosage/adverse effects/analogs & derivatives ,Carboplatin ,Polyethylene Glycols ,chemistry.chemical_compound ,Internal medicine ,Research article ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Doxorubicin ,Aged ,Proportional Hazards Models ,Ovarian Neoplasms ,Aged, 80 and over ,Medicine(all) ,Chemotherapy ,Performance status ,business.industry ,lcsh:R ,General Medicine ,Polyethylene Glycols/administration & dosage/adverse effects ,Middle Aged ,medicine.disease ,Prognosis ,Surgery ,Treatment Outcome ,chemistry ,Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use ,Toxicity ,Female ,business ,medicine.drug - Abstract
Background Platinum-based combinations are the standard second-line treatment for platinum-sensitive ovarian cancer (OC). This randomized phase II study was undertaken in order to compare the combination of carboplatin and pegylated liposomal doxorubicin (LD) with carboplatin and paclitaxel (CP) in this setting. Methods Patients with histologically confirmed recurrent OC, at the time of or more than 6 months after platinum-based chemotherapy, were randomized to six cycles of CP (carboplatin AUC5 + paclitaxel 175 mg/m2, d1q21) or CLD (carboplatin AUC5 + pegylated LD 45 mg/m2, d1q28). Results A total of 189 eligible patients (CP 96, CLD 93), with a median age of 63 years, median Performance Status (PS) 0 and a median platinum free interval (PFI) of 16.5 months, entered the study. Discontinuation due to toxicity was higher in the CP patients (13.5% versus 3%, P = 0.016). The overall response rate was similar: CP 58% versus CLD 51%, P = 0.309 (Complete Response; CR 34% versus 23%) and there was no statistical difference in time-to-progression (TTP) or overall survival (OS; TTP 10.8 months CP versus 11.8 CLD, P = 0.904; OS 29.4 months CP versus 24.7 CLD, P = 0.454). No toxic deaths were recorded. Neutropenia was the most commonly seen severe toxicity (CP 30% versus CLD 35%). More frequent in CLD were severe thrombocytopenia (11% versus 2%, P = 0.016), skin toxicity and Palmar-plantar erythrodysesthesia (PPE) grade 1-2 (38% versus 9%, P< 0.001), while grade 3 neurotoxicity and alopecia were higher in CP (7% versus 0%, P = 0.029, 20% versus 5%, P = 0.003). PS and PFI were independent prognostic factors for TTP and OS. Conclusions The combination of pegylated LD with carboplatin is effective, showing less neurotoxicity and alopecia than paclitaxel-carboplatin. It thus warrants a further phase III evaluation as an alternative treatment option for platinum-sensitive OC patients. Trial Registration Australian New Zealand Clinical Trials Registry: ACTRN12609000436279
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.